BSE · 539470
Shree Ganesh Biotech India Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹24 Cr with net profit ₹0 Cr — a 1.14% net margin, versus 2.91% the period before.
Shareholding
As of 2026-06-30
- Public98.58%
- FII1.42%
1,81,722 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
Not enough history.
52-week position
Where the current price sits in its yearly band
The band spans 1.58× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — GSM · GSM 0. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #85 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,74,684 Cr | 38.19 | 5.68 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,278 Cr | 214.92 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,12,139 Cr | 20.64 | 4.14 | 18.59% | 18.86% |
| Lupin Limited | ₹1,12,118 Cr | 70.4 | 4.99 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,181 Cr | 193.1 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,251 Cr | 344.6 | 18.15 | 16.77% | 13.05% |
| Dr Reddys Laboratories Ltd. | ₹95,311 Cr | 430.91 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,539 Cr | 100.46 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,966 Cr | 546.39 | 2.06 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,746 Cr | 286.6 | 4.9 | 16.66% | 15.65% |
| Shree Ganesh Biotech India Ltd.(this company) | ₹22 Cr | 54 | 0.34 | 0.59% | 10.26% |
AI analysis
AI-generated · google/gemini-2.5-flashShree Ganesh Biotech India Ltd. is listed with a market capitalization of Rs 22 Cr. The company reported revenue of Rs 24.4 Cr and a profit margin of 10.26%. It has a P/E ratio of 56 and an EPS of 0.01.
Positives
- +The company has zero debt, with a debt-to-equity ratio of 0.
- +Return on Equity (ROE) is 59.3%, indicating efficient use of shareholder funds.
- +The company maintains a profit margin of 10.26%.
Negatives
- −Promoter holding is 0%, which can be a concern for corporate governance.
- −Revenue has declined significantly from Rs 72.6949 Cr in Mar 2022 to Rs 24.3985 Cr in Mar 2025.
- −Net profit has also seen a substantial decrease from Rs 2.5259 Cr in Mar 2022 to Rs 0.2784 Cr in Mar 2025.
- −The company reported negative net profit of Rs -0.95 Cr in Mar 2025 and Rs -0.15 Cr in Mar 2026.
- −The company is under GSM surveillance as 'GSM 0'.
Financial Performance
Revenue for the year ending Mar 2025 was Rs 24.3985 Cr. This marks a decrease from Rs 63.0194 Cr in Mar 2023. Net profit for Mar 2025 stood at Rs 0.2784 Cr, a decline from Rs 2.0387 Cr in Mar 2023. Quarterly revenue showed fluctuations, with Rs 2.12 Cr in Mar 2026 and Rs 0.7 Cr in Dec 2025.
Profitability & Returns
The company's profit margin is 10.26%. Return on equity (ROE) is reported at 59.3%, while return on capital employed (ROCE) is 0.8079%. The diluted EPS for the latest period is 0.01.
Balance Sheet
Shree Ganesh Biotech India Ltd. has a book value of Rs 1.6 per share. The debt-to-equity ratio is 0, indicating no debt on the balance sheet. No dividend yield is reported.
Ownership & Pledges
As of June 30, 2026, public shareholding was 98.5789%, with institutions holding 1.4211% (FIIs: 1.4211%, DIIs: 0%). The promoter holding is 0% and there are no promoter pledges. The total number of shareholders was 181,722.
Regulatory & Surveillance
Shree Ganesh Biotech India Ltd. is under GSM surveillance, specifically 'GSM 0'.
Data as of — price: 2026-07-29 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Shree Ganesh Biotech India Ltd.share price & fundamentals